Insights
Insights From Our Experts
Articles
Outlook: Digital & Pharma in Asia Pacific
Asia Pacific is one of the fastest-growing regions for digital innovation in the pharmaceutical and biotechnology industries. Its promising outlook is mainly driven by necessity, commercial flexibility and a broad talent pool. In a candid conversation…
How Pharma Can Meet Commercialization and Marketing Challenges During COVID-19
With a resurgence of COVID-19 cases underway and a second wave of infections on the horizon, the health and economic threats the pandemic poses are not going away any time soon. The crisis has triggered clinical…
Methodology for Predicting Switching Behaviors in Patients
Patient and hub services represent a significant and often ineffective spend surrounding overall patient support. How can we use data and analytics to build better patient services programs that predict next best actions and achieve improved…
Sharpening The Value And Definitions Of Digital And RWD: An Exchange Between Two Industry Leaders
The following is a exchange between Brigham Hyde and Ed Cox, two health tech experts and coworkers on a quest to educate each other and their teams. Note: An inquiry from a colleague who interchanged terminology…
Insights from ISPOR 2020
Shaping the future of patient care. From a panel discussion to podium and workshop presentations, EVERSANA shared insight at this year’s virtual ISPOR 2020 conference. More than 1,300 attended the conference from 54 countries; and our…
CMS Proposed Medicaid Rule: Best Price Impacts of Value-Based Purchasing, Co-Pay Assistance Programs, and More
On June 17, 2020, the Centers for Medicare and Medicaid Services (CMS) published a proposed rule outlining nine specific changes to Medicaid regulations. Five of these directly affect manufacturers through changes in administration of the Medicaid…
Is BeNeLuxA Equipped for a Zolgensma Assessment?
The BeNeLuxA initiative is set to take on Zolgensma (onasemnogene abeparvovec), an innovative gene therapy for children under two years old with spinal muscular atrophy (SMA), which was granted conditional approval for use in Europe in…
Advancing Beyond the Traditional Patient Adherence Model
Delivering value in the era of empowered patients renders the one-size-fit-all patient services program obsolete. Not every treatment journey is consistently linear within a disease state because patients take different paths to medication adherence. For example,…
Accelerating Rare Liver Disease Study Enrollment
An emerging clinical stage biotech contracted with EVERSANA to conduct Phase II trial enrollment support for an ultra-rare liver disease through our Seeker Health platform. Because of the ultra-rare patient population and nature of the therapy,…
Ask the Expert: Digital in Pharma | The Critical Questions
EVERSANA is uniquely positioned to follow the trends and introduce new models and strategies to maximize the value of pharmaceutical products through Digital Medicine Solutions and Execution. Digital Solutions can be deployed to impact the entire…